

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: :

ROBERTS and DEARWESTER :

SERIAL NO.: To be assigned :

Continuation of 09/413,524

FILED: Concurrently herewith : Examiner: To be assigned

FOR: MULTICOMPONENT : Art Unit: To be assigned
CLOSTRIDIAL VACCINES
USING SAPONIN ADJUVANTS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

BOX PATENT APPLICATION

Washington, D.C. 20231

Sir:

Please enter the following amendments prior to examination of the above-identified continuation application and calculation of the filing fee. Applicants believe that no fee is required for submission of this Preliminary Amendment. However, if any fee is required, authorization is provided to charge the required fee to Pfizer Deposit Account No. 16-1445.

IN THE SPECIFICATION:

On page 1 of the specification, before the section entitled "Technical Field," please insert the following sentence: --This is a continuation of application Serial No. 09/413,524, filed October 6, 1999, which is a continuation of application Serial No. 08/536,970, filed September 29, 1995, now U.S. patent No. 6,083,512, which is a 371 of PCT/US94/03395, filed March 29, 1994, which is a continuation of application Serial No. 08/038,428, filed March 29, 1993, abandoned.--

IN THE CLAIMS:

Prior to calculating the filing fee for the above-identified application, please amend the claims as follows.

Please cancel claims 1-17.

Please add the following new claims.

18. (New) A multicomponent clostridial vaccine composition comprising: (i) immunogens from two or more species or serotypes of *Clostridium*; (ii) an antigen derived from a respiratory virus; and (iii) a saponin adjuvant.

19. (New) The vaccine composition of claim 18, comprising immunogens from six or more species or serotypes of *Clostridium*.

REMARKS


Claims 18 and 19 are pending in the application.

New claim 18 is directed to a multicomponent clostridial vaccine composition comprising: (i) immunogens from two or more species or serotypes of *Clostridium*; (ii) an antigen derived from a respiratory virus; and (iii) a saponin adjuvant. This claim is supported in the specification on page 5, on lines 13-14. Applicants submit that nothing in the art made of record in the parent application would have taught or suggested to the person of ordinary skill in the art a vaccine comprising (i) immunogens from two or more species or serotypes of *Clostridium*; (ii) an antigen derived from a respiratory virus; and (iii) a saponin adjuvant.

New claim 19 is directed to the vaccine of claim 18, but comprising immunogens from six or more species or serotypes of *Clostridium*. Applicants again submit that nothing in the art would have taught or suggested such a vaccine.

Respectfully submitted,

Date: January 11, 2001


Alan L. Koller
Attorney for Applicants
Registration No. 37,371
Telephone No. (212) 573-2118